Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Tamoxifen |
Synonyms | |
Therapy Description |
Nolvadex (tamoxifen) is a selective estrogen receptor modulator (SERM), which decreases DNA synthesis and cell growth (NCI Drug Dictionary). Nolvadex (tamoxifen) is FDA approved for breast cancer (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tamoxifen | Nolvadex | ICI-46474 | Hormone Antineoplastics 5 | Nolvadex (tamoxifen) is a selective estrogen receptor modulator (SERM), which decreases DNA synthesis and cell growth and is FDA approved for breast cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01027416 | Phase I | Tamoxifen | Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients | Completed | USA | 0 |
NCT02311933 | Phase II | Z-endoxifen HCl Tamoxifen | Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT01674140 | Phase III | Goserelin Anastrozole Letrozole Leuprolide Everolimus Tamoxifen Exemestane | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | Active, not recruiting | USA | 1 |
NCT02630693 | Phase II | Palbociclib Fulvestrant Tamoxifen | Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer | Completed | CAN | 0 |
NCT00492687 | Phase II | Carboplatin Temozolomide Tamoxifen | Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas | Unknown status | USA | 0 |
NCT01293032 | Phase I | Tamoxifen | Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer | Completed | USA | CAN | 0 |
NCT04272801 | Phase I | Anastrozole Letrozole Tamoxifen Exemestane | Neoadjuvant Endocrine Therapy Tolerance in Geriatric Early Stage ER+ Breast Cancer (Breast52) | Recruiting | USA | 0 |
NCT01124695 | Phase II | Tamoxifen | Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer | Active, not recruiting | USA | CAN | 1 |
NCT04765098 | Phase II | Tamoxifen Lomustine | Tamoxifen Versus Lomustine After First Recurrence in GBM Patients | Not yet recruiting | CAN | 0 |
NCT04129216 | Phase II | Letrozole Tamoxifen Exemestane | The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer | Recruiting | USA | 0 |
NCT02197897 | Phase II | Tamoxifen | Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors | Completed | USA | 0 |
NCT02040857 | Phase II | Exemestane Palbociclib Tamoxifen Letrozole Anastrozole | A Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer | Completed | USA | 0 |
NCT02228681 | Phase II | Tamoxifen Medroxyprogesterone Everolimus + Letrozole | Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT02993159 | Phase II | Afimoxifene Tamoxifen | Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast | Recruiting | USA | 0 |
NCT02269670 | Phase II | Tamoxifen Everolimus Megestrol acetate Letrozole Fulvestrant Anastrozole | Phase II Study of Everolimus Beyond Progression | Active, not recruiting | USA | 0 |
NCT02476786 | Phase II | Anastrozole Fulvestrant Goserelin Tamoxifen Exemestane | Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | Recruiting | USA | 0 |
NCT04123262 | Phase II | Tamoxifen | Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression | Recruiting | USA | 0 |
NCT03917082 | Phase II | Tamoxifen | Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer (LALEAST) | Recruiting | CAN | 0 |
NCT02366130 | Phase II | Tamoxifen Denosumab + Radium Ra 223 dichloride Fulvestrant | Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer | Completed | USA | 0 |
NCT04174352 | Phase I | Tamoxifen | FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT02753686 | Phase I | Tamoxifen Exemestane Fulvestrant Letrozole Anastrozole Everolimus + Exemestane | Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight) | Recruiting | CAN | 0 |
NCT03238703 | FDA approved | Tamoxifen Exemestane Toremifene Anastrozole Letrozole | Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer | Withdrawn | USA | 0 |
NCT01272037 | Phase III | Anastrozole Letrozole Tamoxifen Exemestane | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | Active, not recruiting | USA | CAN | 8 |
NCT03219476 | Phase II | Anastrozole Letrozole Tamoxifen Exemestane | Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02936206 | Phase I | Tamoxifen Fulvestrant | Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. | Terminated | USA | 0 |
NCT02764541 | Phase II | Palbociclib Palbociclib + Tamoxifen Letrozole Tamoxifen | Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) | Active, not recruiting | USA | 0 |
NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed | USA | 0 |
NCT02206984 | Phase I | Tamoxifen Anastrozole Fulvestrant | Endocrine Response in Women With Invasive Lobular Breast Cancer | Recruiting | USA | 0 |
NCT00900744 | FDA approved | Tamoxifen | A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6 | Completed | USA | 0 |